Merck still sees ‘compelling’ outlook for Terns leukemia drug
Summary
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important s...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.